EUVIMEDEUVIMED entdecken
Kohortenstudie

Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study

Lukas Röthlisberger, Manuela Albisetti, Alessandra Bosch iD

Hämostaseologie · 29.07.2026

DOI: 10.1055/a-2918-8110 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Hämostaseologie, erschienen am 29.07.2026. Verfasst von Lukas Röthlisberger und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Children's Hospital Zürich, Department of Haematology, ZH, Switzerland, Zürich.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Direct oral anticoagulants (DOACs) show increasing popularity in the treatment of paediatric venous thromboembolism (VTE), but real-world evidence outside clinical trials remains scarce.

Objectives

This study aimed to evaluate the use, safety and effectiveness of rivaroxaban in a real-world paediatric cohort at a tertiary care hospital.

Methods

All children exposed to rivaroxaban between January 2020 and June 2025 at our institution were included into this single-centre retrospective cohort study. In chart reviews, effectiveness was assessed as thrombus recurrence, progression, resolution, or improvement; safety outcomes included clinically relevant bleeding (CRB) and minor bleeding.

Results

Fifty-seven children were included at a median age of 13.8 years (IQR 7.1–15.6); 49% were female. In the treatment group (n = 37), one thrombosis recurred (3%), with thrombus resolution in 19 (54%) and radiologic improvement in 5 patients (14%). In the prophylaxis group (n = 20), no incident VTE occurred. Overall, CRB was rare (7%), all non-major during rivaroxaban exposure and occurred exclusively in children with identifiable additional bleeding risk factors.

Conclusions

Rivaroxaban demonstrated a favourable effectiveness and safety profile in this real-world paediatric cohort, with outcomes comparable to available real-world and trial data. CRB events clustered in settings with additional bleeding risks, underscoring the importance of patient characteristics in guiding therapy. Our findings support rivaroxaban as a feasible anticoagulation option in children.

Autor:innen und Institutionen

  • University Children's Hospital Zürich, Department of Haematology, ZH, Switzerland, Zürich.
  • University of Zurich, Faculty of Medicine, ZH, Switzerland, Zürich.

ORCID-Profile: Alessandra Bosch

Zitieren

APA

Röthlisberger, L., Albisetti, M., & Bosch, A. (2026). Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study. Hämostaseologie. https://doi.org/10.1055/a-2918-8110

Vancouver

Röthlisberger L, Albisetti M, Bosch A. Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study. Hämostaseologie. 2026. doi:10.1055/a-2918-8110

BibTeX
@article{Rthlisberger2026,
  author = {Röthlisberger, Lukas and Albisetti, Manuela and Bosch, Alessandra},
  title = {Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study},
  journal = {Hämostaseologie},
  year = {2026},
  doi = {10.1055/a-2918-8110}
}
Kostenlos starten →